GT Biopharma, Inc.GTBPNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank77
3Y CAGR+218.9%
5Y CAGR-20.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+218.9%/yr
vs -75.2%/yr prior
5Y CAGR
-20.9%/yr
Recent acceleration
Acceleration
+294.1pp
Accelerating
Percentile
P77
Within normal range
vs 5Y Ago
0.3x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 117.03% |
| Q3 2025 | 74.66% |
| Q2 2025 | -66.97% |
| Q1 2025 | -43.06% |
| Q4 2024 | 47.67% |
| Q3 2024 | -26.74% |
| Q2 2024 | 129.60% |
| Q1 2024 | -42.74% |
| Q4 2023 | -0.51% |
| Q3 2023 | -34.89% |
| Q2 2023 | 26.97% |
| Q1 2023 | -41.94% |
| Q4 2022 | 3.61% |
| Q3 2022 | 140.83% |
| Q2 2022 | -45.42% |
| Q1 2022 | -66.89% |
| Q4 2021 | 525.40% |
| Q3 2021 | 57.75% |
| Q2 2021 | -61.04% |
| Q1 2021 | 603.86% |
| Q4 2020 | 377.38% |
| Q3 2020 | -800.00% |
| Q2 2020 | -96.30% |
| Q1 2020 | 3950.00% |
| Q4 2019 | -98.81% |
| Q3 2019 | 335.71% |
| Q2 2019 | -81.53% |
| Q1 2019 | -32.31% |
| Q4 2018 | 10.89% |
| Q3 2018 | -65.83% |
| Q2 2018 | -6.39% |
| Q1 2018 | 2112.10% |
| Q4 2017 | -70.15% |
| Q3 2017 | 118.26% |
| Q2 2017 | 67.36% |
| Q1 2017 | -42.40% |
| Q4 2016 | 0.00% |
| Q3 2016 | 0.00% |
| Q2 2016 | 11.11% |
| Q1 2016 | -57.14% |